Short Subjects

Complete Regression of Retinoblastoma Following Intra-Arterial Chemotherapy

Nina Ni, BA; Carol L. Shields, MD; Carlos G. Bianciotto, MD; Pascal M. Jabbour, MD; Robert H. Rosenwasser, MD; Jerry A. Shields, MD

  • Journal of Pediatric Ophthalmology and Strabismus
  • DOI: 10.3928/01913913-20110531-02
Rights and Permissions

Abstract

A 22-month-old girl with Group C unilateral retinoblastoma demonstrated dramatic tumor regression after two infusions of 5 mg of intra-arterial melphalan as primary therapy. Complete tumor control without recurrence was noted at 1 year. Retinal and choroidal perfusion was intact and the electroretinogram improved following therapy.

AUTHORS

From the Ocular Oncology Service (NN, CLS, CGB, JAS), Wills Eye Institute, and the Department of Neurological Surgery (PMJ, RHR), Thomas Jefferson University, Philadelphia, Pennsylvania.

Supported by the Retina Research Foundation of the Retina Society in Cape Town, South Africa (CLS), and the Eye Tumor Research Foundation, Philadelphia, Pennsylvania (CLS).

The authors have no financial or proprietary interest in the materials presented herein.

Address reprint requests to Carol L. Shields, MD, Ocular Oncology Service, Suite 1440, Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107. E-mail: carol.shields@shieldsoncology.com

doi: 10.3928/01913913-20110531-02

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.

[X]